Loading...

Biovica receives order worth 100 000 USD

Uppsala, Sweden 2018-03-20  Biovica has received an order for the company's DiviTum® product from a global diagnostic and contract research company (CRO company). DiviTum will be used during the development of a new targeted drug against cancer to study the effectiveness of the treatment.

2018-04-20T04:29:31+00:00 March 20th, 2018 08:00|Press Release|

New Operations Manager at Biovica

Uppsala, December 5, 2017. Biovica has appointed Adam Germunder as new Operations Manager. Adams responsibilities include to build and secure the company’s production capabilities and ensure that they meet regulatory requirements in preparation for the commercialization of DiviTum®.

2018-04-20T04:29:31+00:00 December 5th, 2017 08:30|Press Release|

Researchers at Washington University report: DiviTum® can evaluate the biologic activity of blockbuster breast cancer drug after two weeks

Uppsala, Sweden, November 23, 2017. Results of a study from Washington University, St Louis, demonstrate that the DiviTum® can evaluate the biologic activity of Pfizer’s breast cancer drug palbociclib (Ibrance®) in just two weeks are published in the latest edition of the scientific journal Breast Cancer Research and Treatment. This shortening of the response evaluation window can improve outcome and increase quality of life for breast cancer patients.

2018-04-20T04:29:31+00:00 November 23rd, 2017 08:00|Press Release|

New Swedish study results at SABCS show DiviTum® blood test reduces waiting times for evaluating breast cancer treatment

Uppsala, Sweden, November 14, 2017. Results from a study of 142 women with newly diagnosed metastatic breast cancer will be presented by researchers from Lund University at the world’s biggest breast cancer conference in San Antonio, USA. The study demonstrates that the DiviTum® blood-based biomarker can provide more accurate prognosis than today’s standard methods. 

2018-04-20T04:29:32+00:00 November 14th, 2017 08:00|Press Release|